Tag Archives: ICBC

Engineering Consistency: Inside the Push for GMP-Compliant Cannabis

By Shawna Seldon
No Comments

As cannabis becomes a globally traded medical commodity, cGMP compliance is reshaping how it is grown, handled, and transported. For operators working with imported biomass, controlling contamination and ensuring consistency across supply chains has become a defining challenge. That challenge was a central focus at the International Cannabis Business Conference in Berlin, where a panel on Good Manufacturing Practices (GMP) examined how operators can meet the European Union’s stringent standards for medical cannabis.

Moderated by Constant Ma, CEO & President of Cannactions Consulting Ltd., the session brought together cultivators, scientists, and technology providers to discuss contamination risk from cultivation through post-harvest processing and packaging.

Unlike many agricultural commodities, cannabis presents a distinct compliance challenge. It is a biological product, inherently variable from batch to batch, and highly susceptible to microbial contamination. In medical markets, particularly in Europe, variability must be tightly controlled.

“All of this is super important because with GMP, we have to make sure that our products are consistent at all times,” Ma said. “And we also have to make sure that it’s safe for the patients that are using it.”

Where Contamination Risk Begins

Panelists emphasized that contamination risk does not begin in processing. It starts in cultivation and carries through every stage of production.

Matthieu van der Born, CEO & Founder of Flower Power, is transitioning operations from Good Agricultural and Collection Practices (GACP) to GMP, pointing to labor-intensive processes such as hand-trimming as a source of risk. High personnel density increases touchpoints, while environmental systems must account for both plant material and human activity.

Rui Soares, CEO of Paralab Green, stressed that early-stage decisions, including facility design, nutrients, and environmental controls, have lasting downstream impacts. “If you invest for quantity and not for quality, you have no future,” he said, reinforcing a recurring theme: contamination is often the result of upstream compromises.

The Critical Window: Post-Harvest

The discussion turned to post-harvest handling, widely viewed as the most vulnerable phase for microbial growth. Ed Wells, Vice President of Sales at Cannatrol, framed the issue as a risk management matter. “At the heart of GMP, you are identifying risk, then you’ve got to mitigate that risk so you have safe and predictable outcomes,” he said.

Once cannabis is harvested, microbial populations can expand rapidly if environmental conditions are not tightly controlled. The key variable is water activity: the moisture available to support microbial growth. Until the product reaches shelf stability, microbial load can continue to increase.

“The name of the game is to provide an environment where that flower becomes shelf stable as soon as possible,” Wells said. “That is your window of risk.”

That window is shaped by both process design and operations. Traditional methods, such as hanging whole plants, can extend drying time and prolong exposure. More controlled approaches, such as reducing biomass earlier and optimizing environmental conditions, can shorten that timeline, though they may require greater coordination of labor.

Joseph Edwards, Chief Scientist & Vice President of Deconix, described post-harvest cannabis as a “parasitic host relationship,” where microbial organisms continue to thrive on plant material. Without precise control of humidity, temperature, and airflow, the risk of contamination escalates quickly.

Decontamination vs. Prevention

A central tension in GMP compliance is the role of decontamination. While remediation technologies are widely used, panelists agreed they should not be the primary line of defense. Soares emphasized that microbial reduction should not be treated as a default step, but as a corrective measure when prevention fails, aligning with GMP principles that prioritize process control over downstream intervention.

Still, decontamination remains necessary when microbial levels exceed thresholds. George Terry, Executive Vice President of Rad Source, noted that technologies such as X-ray-based systems can help ensure compliance, particularly for export into regulated markets. The broader takeaway is that GMP compliance relies on layered controls: facility design, environmental management, operational discipline, and, when needed, remediation.

Planning, Cost, and Differentiation

The panel also addressed the economic realities of GMP compliance. Building a compliant facility requires significant upfront investment, and poor planning can lead to costly retrofits.

“Don’t set yourself up to have to spend good money after bad,” Wells said, advising operators to prioritize systems that improve both product quality and operational efficiency.

 As markets mature and pricing compresses, differentiation becomes critical. Consistency—delivering the same product profile batch after batch—was repeatedly cited as a competitive advantage, particularly in medical markets where patients rely on predictable outcomes.

Panelists drew comparisons to pharmaceuticals and consumer goods, where consistency is non-negotiable. Variability in a medical product would be unacceptable.

A Maturing Standard

The discussion reflects an industry in transition. While GMP standards are well established in pharmaceuticals, their application to cannabis is still evolving, shaped by regulation and the biological complexity of the plant.

What is clear is that expectations are rising, especially in Europe. As more markets adopt GMP requirements, operators must approach cultivation, processing, and quality assurance as an integrated system rather than discrete steps.

For medical cannabis, patient safety, product consistency, and regulatory compliance are no longer aspirational. They are baseline requirements. And as the panel made clear, meeting those requirements begins long before the product reaches the patient.

margueriteICBC

Berlin’s ICBC: Meeting the European Cannabis Industry

By Marguerite Arnold
1 Comment
margueriteICBC

The International Cannabis Business Conference (ICBC) in Berlin is now officially over. The speeches have been made, the parties have been attended. The hard-working crew behind it all has wrapped up, checked out and is off to Vancouver. And most of all, the marathon of meetings and deal discussions that were the mark of this budding and certainly by now established market are done. Even if there are still details to be ironed out in all the new business in the coming months.

As always, the dilemma for conference attendees was how to spend the limited time in this concentrated cannabis gathering. With all of the networking and excitement, people still wanted to hear the experts who spoke on topics ranging from cannabis financing to actually doing business in Germany to new medical advances. Traffic in the expo section was also heavy, as attendees visited the wide range of vendors. Producers and distributors of both plant and derived product were present, along with vape companies brave enough to compete with Storz and Bickel on their own turf, various tech solutions and of course, international consultants.

As the dust clears and the contracts get signed, what are the takeaways from the second edition of the ICBC in Berlin?

Germany Is Going Green

The simplest takeaway? The ICBC Berlin is not a market to be missed in the future for the global cannabis executive. Even if you are an American firm (and for the most part still largely excluded from a rapidly expanding worldwide trade that is establishing itself now with authority), you need to be here. The contacts you make are global, and you do not want to be left out. For foreign investors interested in this market, it is a must. For everyone else, this is a meet and greet, not to mention education, barnone. The German medical and even prosumer CBD market is attracting the world.

Yes, there have been ups and downs even in the last three weeks that include the crashing of the German bid along with news stateside that the Trump Administration is going to hang Jeff Sessions out to dry for Russia with his latest “Make American States Great For Cannabis Again” contortion.

Guenther Weiglein
Guenther Weiglein, activist patient, being interviewed in front of MedPayRx booth

But here on the other side of the Atlantic, it is clear that the federal cannabinoid horse has left the barn. There are now rumorsfloating that the bid is not yet entirely dead (now apparently in a legal purgatory of appeals and even potentially “bid amendments”) that nobody is willing to go on record to discuss. Beyond that, however, as was clear from the frenzied deal-makingon the floor and off it at the ICBC, the market is open, distributors are finding new channels to move product, and patients demanding access are not leaving the streets.

Far from it. In fact, the budding nascent umbrella national non-profit campaign designed to open access for patients and educate doctors, The German Patients Roundtable, had a huge second meeting during the conference, with both German and international attendees from countries including Israel and South Africa.

The CBD and THC genie cannot be stuffed back into the local bottle. And everyone knows it. This is federal medical reform, and even better, covered under German national public health insurance. Despite the hiccups and challenges that still remain, this is open blue water for a medical market that has never existed anywhere to date.

ICBC logoAnyone with a GMP facility, Euro cleared export rights and crop or product ready to ship will be welcome here in a market that at this point, cannot get enough plant or oil. Edibles are still a to-come discussion.

To the extent that this is also negative, it is very clear that the market is still highly inefficient. Producers who do have productare not being found by those on the ground who want to sell it to patients. That will also begin to change. But for now, many on the ground are playing a digitalized Rolodex game of “who do you know” that still consists of personal emails between conference-met colleagues if not LinkedIn contacts and impromptu (and freebie) favors. Those who hope to gain an income merely by connecting the source of product and outlets the old fashioned way are also about to be left in the dust by a market that will not be held back and activist businesses who are eyeing both the United States and Canada right now (if not Israel and Australia), and translating all of that into both euros and German.

It is also very clear that the savvy Germans who were largely left out of the bid proceedings last time do not mean to sit this party out – and are angling to get into the game however they can. This is taking some interesting forms, but processing and testing are going to be huge issues of the market here for a long time to come. And so is home-grown, high-quality CBD. The German government is even offering tax credits for growing certain kinds of hempright now. Sound familiar Kentucky?

Trends and Takeaways

It is not just the Canadians who are going to get market share. The Canadian LPs are still in a good position to dominate the early market but it is clear that there is still room for others to enter. Whether the government allows an appeal of the court’s decision to hold up, there is a quick bid “redo” for the top 10 finalists, or a second bid, the market has now arrived and is in its second year.

margueriteICBC
Marguerite Arnold presents on the impact of blockchain on the cannabis industry

CBD is going to be an important path to other kinds of provision and cultivation. Despite the widespread misconceptions about Germany being a “CBD only” market (it is not), it is clear that a consumer CBD only strategy will be an interesting path into the market here but not one for the faint of heart. The Canadian companies in particular are beginning to move into the realm of big pharma (their market caps certainly are). But it is also clear that more local competition is hip to the same. And as a result, even this part of the market will be a highly competitive one.

German firms are first at this gate, beyond the big Canadian LPs, but they are not the only ones now in the market. See Dutch, Austrian and Swiss firms, many with pharmaceutical company credits and market entry already under their belt.  Not to mention producers from both Greece and the Baltics. Everyone on the import side is eyeing the opening market and stalled bid as a fantastic opportunity. Look for products from these locales as testing and certification protocols become more effective.

Central to all of these developments? The conference is theplacefor the global cannabis industry to meet and get to know one another, put together by Alex Rogers and a seasoned, international team behind the ICBC.